We use a few cookies

Essential cookies keep the library working. With your permission, we'd also like to use analytics to see what's useful and improve the experience. Read our Privacy Policy or Cookie Policy.

Skip to main content
Home/e-Resources/Medical Sciences/Epidemiology of neuromyelitis optica in Latin America
PeriodicalsMedical Sciences

Epidemiology of neuromyelitis optica in Latin America

Checking your access to this record.

Abstract & Overview

A major development over the past two decades was the recognition of recurrent neuromyelitis optica (NMO) as a particular central nervous system disorder different from multiple sclerosis (MS). Here we reviewed the epidemiology of NMO in Latin America (LATAM). A predominance of a mixed population is found in this region. Recurrent NMO in black women was described in the Caribbean Islands and in Rio de Janeiro. The prevalence of NMO in LATAM varied from 0.37/100,000 (Volta Redonda city) to 4.2/100,000 inhabitants (Caribbean Islands). NMO differs significantly from MS with respect to gender, ethnicity, morbidity and genetic susceptibility. An association of the HLA DRB1*03 alleles with NMO was described in the French Antilles, Ribeirão Preto, Rio de Janeiro and Mexico. It is not common to find familial forms of NMO. NMO represents 11.8% of all inflammatory idiopathic diseases in South America (SA). In SA, the highest frequency of NMO occurs in African Brazilian young women. The overall relative frequency of NMO among MS cases in this region was 14%, decreasing following a north-south gradient, which parallels the percentage of nonwhite people.

Cite this record

MP Alvarenga, Sérgio Luís Schimidt, Alvarenga R.M.P. (2017). Epidemiology of neuromyelitis optica in Latin America. Multiple Sclerosis Journal - Experimental Translational and Clinical, 3(3), 2055217317730098–2055217317730098. https://doi.org/10.1177/2055217317730098

Copy in another style

Alvarenga, M., Schimidt, S. L., & R.M.P., A. (2017). Epidemiology of neuromyelitis optica in Latin America. Multiple Sclerosis Journal - Experimental Translational and Clinical, 3(3), 2055217317730098–2055217317730098. https://doi.org/10.1177/2055217317730098
Author names are used as deposited, so check their order before you submit.

Metadata is harvested from open-access indexes and can be incomplete. Check a citation against the published version before relying on it — see our open access & attribution policy.